{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:48:26Z","timestamp":1782442106806,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.beha.2017.07.008","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T21:01:52Z","timestamp":1501794112000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["How should we treat the AYA patient with newly diagnosed ALL?"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":false,"given":"Nicolas","family":"Boissel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000\u201307: population-based data from EUROCARE-5","volume":"17","author":"Trama","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cncr.29870","article-title":"Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future","volume":"122","author":"Smith","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/cncr.29866","article-title":"Social well-being among adolescents and young adults with cancer: a systematic review","volume":"122","author":"Warner","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/cncr.29834","article-title":"Reimagining care for adolescent and young adult cancer programs: moving with the times","volume":"122","author":"Gupta","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2141.2008.07417.x","article-title":"Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia","volume":"144","author":"Harrison","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2017.07.008_bib6","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.leu.2403000","article-title":"Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup","volume":"17","author":"Soulier","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Moorman","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.beha.2017.07.008_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","article-title":"IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome","volume":"32","author":"Russell","year":"2014","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A\u00a0subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.beha.2017.07.008_bib11","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.beha.2017.07.008_bib14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMc1412123","article-title":"Ph-like acute lymphoblastic leukemia in older adults","volume":"371","author":"Herold","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2017.07.008_bib17","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib18","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib19","doi-asserted-by":"crossref","first-page":"e26328","DOI":"10.1002\/pbc.26328","article-title":"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.beha.2017.07.008_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/leu.2013.277","article-title":"An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions","volume":"28","author":"Clappier","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2017.07.008_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.3535","article-title":"Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults","volume":"48","author":"Yasuda","year":"2016","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2017.07.008_bib24","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2017.07.008_bib25","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood-2003-11-3944","article-title":"Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy","volume":"104","author":"Asnafi","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib27","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3324\/haematol.2013.086082","article-title":"The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest","volume":"98","author":"Ben Abdelali","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2017.07.008_bib29","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.07.008_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult ETP-ALL: a GRAALL study","author":"Bond","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"5694","key":"10.1016\/j.beha.2017.07.008_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.beha.2017.07.008_bib32","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to \u03b3-secretase inhibitors","volume":"204","author":"O'Neil","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib33","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2005-12-4956","article-title":"Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia","volume":"108","author":"Breit","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2017.07.008_bib34","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","article-title":"NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study","volume":"113","author":"Asnafi","year":"2009","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.beha.2017.07.008_bib35","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.beha.2017.07.008_bib36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM199310283291810","article-title":"Acute lymphoblastic leukemia \u2013 progress in children, less in adults","volume":"329","author":"Hoelzer","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib38","first-page":"1954","article-title":"Difference in outcome of adolescents with acute lymphoblastic leukemia (all) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols","volume":"104","author":"Testi","year":"2004","journal-title":"ASH Annu Meet Abstr"},{"issue":"12","key":"10.1016\/j.beha.2017.07.008_bib39","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in The Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib40","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cncr.22189","article-title":"Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol","volume":"107","author":"Hallb\u00f6\u00f6k","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib42","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?","volume":"21","author":"Schiffer","year":"2003","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"10.1016\/j.beha.2017.07.008_bib44","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1200\/JCO.2008.20.8959","article-title":"Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group","volume":"27","author":"Nachman","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib45","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on dana-farber cancer Institute acute lymphoblastic leukemia consortium protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","article-title":"Improved prognosis for older adolescents with acute lymphoblastic leukemia","volume":"29","author":"Pui","year":"2011","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib48","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib49","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2011.141","article-title":"Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40","volume":"25","author":"Rijneveld","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2017.07.008_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3561.3561","article-title":"Dose-intensity impacts on survival of adolescents and young adults with acute lymphoblastic leukemia treated in adult departments by a pediatric protocol (FRALLE 2000BT)","volume":"120","author":"Cluzeau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.07.008_bib51","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.beha.2017.07.008_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (all): early results of U.S. Intergroup trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2017.07.008_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2017.07.008_bib55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2017.07.008_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.839.839","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-014-0210-9","article-title":"Pediatric-like therapy for adults with ALL","volume":"9","author":"Dombret","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"22","key":"10.1016\/j.beha.2017.07.008_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.762.762","article-title":"The upper age limit for a pediatric-inspired therapy in younger adults with Ph-negative acute lymphoblastic leukemia (ALL)? Analysis of the Graall-2005 study","volume":"128","author":"Huguet","year":"2016","journal-title":"Blood"},{"issue":"suppl 5","key":"10.1016\/j.beha.2017.07.008_bib59","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib60","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","article-title":"Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis","volume":"121","author":"Gupta","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission: chemotherapy versus allogeneic HCT in ALL","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.beha.2017.07.008_bib63","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2017.07.008_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.552.552","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome (Ph)-Negative acute lymphoblastic leukemia (all): results from the group for research on adult all (GRAALL)","volume":"122","author":"Dhedin","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2017.07.008_bib65","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2017.07.008_bib66","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2017.07.008_bib67","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","article-title":"A\u00a0sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study","volume":"101","author":"Chiaretti","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib68","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's Oncology Group Study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.beha.2016.10.009","article-title":"Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?","volume":"29","author":"Litzow","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib70","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2017.07.008_bib71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","article-title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib72","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2017.07.008_bib73","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2017.07.008_bib74","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib75","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/jayao.2015.0014","article-title":"Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase","volume":"4","author":"Boissel","year":"2015","journal-title":"J\u00a0Adolesc Young Adult Oncol"},{"issue":"5","key":"10.1016\/j.beha.2017.07.008_bib76","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.leu.2401007","article-title":"Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia","volume":"12","author":"Larson","year":"1998","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib77","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2017.07.008_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3903.3903","article-title":"Frontline-treatment of acute lymphoblastic leukemia (all) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (Alliance)","volume":"122","author":"Advani","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib79","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols: thrombosis in Acute Lymphoblastic Leukaemia","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2017.07.008_bib80","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A\u00a0randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib81","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib82","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1538-7836.2007.02383.x","article-title":"Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis","volume":"5","author":"Caruso","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.beha.2017.07.008_bib83","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.13162","article-title":"Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology","volume":"168","author":"Ranta","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib84","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ajh.24130","article-title":"Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with L-asparaginase: the GRAALL experience","volume":"90","author":"Couturier","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2017.07.008_bib85","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"10.1016\/j.beha.2017.07.008_bib86","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"s1","key":"10.1016\/j.beha.2017.07.008_bib87","article-title":"Tolerance, compliance and efficacy of L-asparaginase during induction phase in adult philadelphia-negative acute lymphoblastic leukemia: experience of the GRAALL-2005","volume":"101","author":"Balsat","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2017.07.008_bib88","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.beha.2017.07.008_bib89","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","article-title":"Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"111","author":"Mody","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2017.07.008_bib90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ije\/dyu031","article-title":"Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort)","volume":"44","author":"Berbis","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.beha.2017.07.008_bib91","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3324\/haematol.2012.081265","article-title":"Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood","volume":"98","author":"Girard","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2017.07.008_bib92","doi-asserted-by":"crossref","first-page":"e0151433","DOI":"10.1371\/journal.pone.0151433","article-title":"Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.beha.2017.07.008_bib93","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1470-2045(12)70274-7","article-title":"Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial","volume":"13","author":"Mattano","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.beha.2017.07.008_bib94","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3324\/haematol.2016.147595","article-title":"Osteonecrosis in children with acute lymphoblastic leukemia","volume":"101","author":"Kunstreich","year":"2016","journal-title":"Haematologica"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T05:06:24Z","timestamp":1602651984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1521692617300257"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.07.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How should we treat the AYA patient with newly diagnosed ALL?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}